Biocorp announces that, following receipt of the usual regulatory approvals, it has completed the off-market acquisition by Novo Nordisk of a total of 2,838,669 shares, representing 64.3% of the company's capital and 64.09% of its voting rights, at a price of 35 euros per share.

The outstanding convertible bonds issued by Biocorp were redeemed in full in cash on this occasion, and the composition of Biocorp's Board of Directors was modified to take account of the new shareholder structure.

Novo Nordisk will file with the AMF in the next few days a proposed simplified tender offer (OPAS) to acquire the remaining shares, followed by a squeeze-out if the required conditions are met.

Copyright (c) 2023 CercleFinance.com. All rights reserved.